AstraZeneca will present pooled efficacy and cardiovascular safety analyses from the phase III clinical programme of roxadustat for the treatment of anaemia from chronic kidney disease (CKD) in non dialysis─dependent...
Latest articles
EMA’s safety committee recommends restriction on use of Lemtrada for multiple sclerosis patients
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) committee has recommended restrictions on the use of Lemtrada (alemtuzumab) in patients with relapsing remitting multiple...
EMA’s PRAC committee recommends Xeljanz to be used with caution for all patients at high risk of blood clots
A review by the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) committee has concluded that Xeljanz (tofacitinib) could increase the risk of blood clots in the lungs and in...
Astellas' Xospata gets European approval as monotherapy for patients with relapsed/refractory AML with FLT3 mutation
Astellas Pharma Inc. announced that the European Commission (EC) has approved the oral once─daily therapy Xospata (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory
Eerste Emerce Update gewijd aan online beveiliging en privacy
De eerste sprekers voor Emerce Update #7: Security Make sure you secure, op 10 december in B. Amsterdam, zijn bekend. Het is de eerste Update van Emerce gewijd aan online beveiliging. Ivana Bartoletti (Gemserv &...
Novartis gets European approval to update Cosentyx label to include dosing flexibility in ankylosing spondylitis
Novartis, a leader in rheumatology and immuno─dermatology, announced that the European Commission (EC) has approved a label update for the up─titration of Cosentyx (secukinumab) to 300 mg for patients with...
